Key facts
- Hinge Bio’s last known valuation is $46.0M (Jan 2025).
- It has raised $66.8M across 4 recorded rounds; the latest was Early Stage VC ($30.6M) in Dec 2024.
- Notable investors include US National Science Foundation, Springboard Enterprises, United States Department of War, Evolution VC Partners, Baruch Future Ventures — 13 tracked in total.
- Hinge Bio has filed 6 Form Ds with the SEC since 2020, most recently Jan 2025 ($30.6M sold to 82 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Hinge Bio
Funding rounds
4 roundsAbout Hinge Bio
Operator of a biotech company intended to work for the development of a new class of flexible, extendible, and cooperatively binding therapeutics and diagnostics. The company focuses on facilitating therapeutics capable of simultaneously binding either one disease target with multiple hands and targeting different oncology, metabolic disease, and neurodegenerative disorders, enabling medical providers to diagnose diseases at an early stage and provide proper treatment.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Burlingame, CA, United States
- Founded
- 2015
- Employees
- 18
- Website
- hingebio.com/
- Ownership
- Privately Held (backing)
Hinge Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hinge Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hinge Bio in its N-PORT filings yet. We sweep new filings monthly.